{"id":154700,"date":"2026-11-18T17:07:19","date_gmt":"2026-11-18T08:07:19","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4884-20261118-01_wp_capital_policy\/"},"modified":"2026-11-18T17:07:19","modified_gmt":"2026-11-18T08:07:19","slug":"4884-20261118-01_wp_capital_policy","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261118-01_wp_capital_policy\/","title":{"rendered":"Notice Regarding Determination of Terms for Issuance of Shares by Third-Party Allotment and Issuance of the 19th and 20th Stock Acquisition Rights (with Option for Exercise Price Adjustment Provision)"},"content":{"rendered":"<p>Decided on third-party allotment of new shares (567,100 shares and allocation of 567,100 shares + 378,000 shares to Maruishi Pharmaceutical and Xenoac HD respectively) and issuance of stock acquisition rights (total 21,460 units; 19th series exercise price 270 yen, 20th series 235 yen). Raising total funds of approximately 2,206 million yen (net proceeds), with main uses including preparation for a Phase III clinical trial in the U.S. for acute spinal cord injury, establishment of manufacturing system for recombinant human HGF protein active pharmaceutical ingredient, domestic API manufacturing, and working capital. Maximum dilution is about 35.97%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4884","jir_company_name":"Kringle Pharma, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-18","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4884-20261118-01.pdf","jir_short_summary":"Decided on third-party allotment of new shares (567,100 shares and allocation of 567,100 shares + 378,000 shares to Maruishi Pharmaceutical and Xenoac HD respectively) and issuance of stock acquisition rights (total 21,460 units; 19th series exercise price 270 yen, 20th series 235 yen). Raising total funds of approximately 2,206 million yen (net proceeds), with main uses including preparation for a Phase III clinical trial in the U.S. for acute spinal cord injury, establishment of manufacturing system for recombinant human HGF protein active pharmaceutical ingredient, domestic API manufacturing, and working capital. Maximum dilution is about 35.97%.","jir_summary":"### Overview of Capital Policy\nKringle Pharma, Inc. has resolved to issue new shares by third-party allotment and to issue the 19th and 20th series of stock acquisition rights. The allotment recipients are Maruishi Pharmaceutical Co., Ltd. and Xenoac Holdings Co., Ltd., to be allotted 567,100 shares and 378,000 shares respectively. The stock acquisition rights total 21,460 units (10,730 units each), with subscription prices of 270 yen for the 19th series and 235 yen for the 20th series. Total funds amount to approximately 2,216 million yen, and the use of proceeds includes expenses to advance preparation for a Phase III trial in the U.S. for acute spinal cord injury, establishment of manufacturing capacity for recombinant human HGF protein active pharmaceutical ingredient, domestic API manufacturing, and working capital.\n\n### Impact on Shareholders and Outlook\nDilution is expected to be up to approximately 35.97%, and a third-party committee reviewed the reasonableness following exchange deliberations. The use of proceeds aims to accelerate growth strategy and target future enhancement of corporate value. Exercise price adjustment mechanisms and floors are set under certain conditions to appropriately manage shareholder impact. Following the implementation of the capital policy, attention should be paid to changes in shareholding ratios of Maruishi Pharmaceutical and Xenoac HD and movements of major shareholders.","jir_financial_highlights":"Amount raised (estimated net proceeds): 2,206,176,550 yen (Unknown)\nNumber of new shares issued: 945,100 shares (Unknown)\nTotal number of stock acquisition rights: 21,460 units (Unknown)","jir_category":"","jir_hashtags":"#KringlePharma, #CapitalPolicy, #StockAcquisitionRights, #PublicOffering, #ShareAllotment","jir_key_figures":"Total funds raised: 2,222,176,550 yen \u2192 Estimated net proceeds 2,206,176,550 yen\nTotal number of shares offered: 945,100 shares\nTotal number of stock acquisition rights: 21,460 units\nAllotment recipients: Maruishi Pharmaceutical 567,100 shares, Xenoac HD 378,000 shares\nDilution rate: Maximum approx. 35.97%","jir_meta_title":"Kringle Pharma, Inc. - Determination of Third-Party Allotment and Issuance of Stock Acquisition Rights | U.S. Clinical Trial Funding","jir_meta_description":"Kringle Pharma, Inc. has resolved to issue new shares by third-party allotment and issue stock acquisition rights. Allotment recipients are Maruishi Pharmaceutical and Xenoac HD. Use of proceeds includes U.S. clinical trial preparation, manufacturing capacity build-out and working capital. Estimated dilution approx. 35.97%.","jir_og_title":"Kringle Pharma, Inc. - Decision to Issue New Shares and Stock Acquisition Rights | Use of Proceeds & Dilution","jir_og_description":"Resolved third-party allotment of new shares and issuance of stock acquisition rights. Funds approx. 2,216 million yen, main uses include U.S. clinical trial preparation, manufacturing capacity establishment and domestic API manufacturing. Maximum dilution approx. 35.97%.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60827,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-154700","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notice Regarding Determination of Terms for Issuance of Shares by Third-Party Allotment and Issuance of the 19th and 20th Stock Acquisition Rights (with Option for Exercise Price Adjustment Provision) - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261118-01_wp_capital_policy\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261118-01_wp_capital_policy\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261118-01_wp_capital_policy\/\",\"name\":\"Notice Regarding Determination of Terms for Issuance of Shares by Third-Party Allotment and Issuance of the 19th and 20th Stock Acquisition Rights (with Option for Exercise Price Adjustment Provision) - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-18T08:07:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261118-01_wp_capital_policy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261118-01_wp_capital_policy\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261118-01_wp_capital_policy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Notice Regarding Determination of Terms for Issuance of Shares by Third-Party Allotment and Issuance of the 19th and 20th Stock Acquisition Rights (with Option for Exercise Price Adjustment Provision)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Notice Regarding Determination of Terms for Issuance of Shares by Third-Party Allotment and Issuance of the 19th and 20th Stock Acquisition Rights (with Option for Exercise Price Adjustment Provision) - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261118-01_wp_capital_policy\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261118-01_wp_capital_policy\/","url":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261118-01_wp_capital_policy\/","name":"Notice Regarding Determination of Terms for Issuance of Shares by Third-Party Allotment and Issuance of the 19th and 20th Stock Acquisition Rights (with Option for Exercise Price Adjustment Provision) - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-18T08:07:19+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261118-01_wp_capital_policy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261118-01_wp_capital_policy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261118-01_wp_capital_policy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Notice Regarding Determination of Terms for Issuance of Shares by Third-Party Allotment and Issuance of the 19th and 20th Stock Acquisition Rights (with Option for Exercise Price Adjustment Provision)"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"60827","title":"KRINGLE PHARMA INC","ticker":"4884"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/154700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=154700"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/154700\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=154700"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=154700"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=154700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}